KURA Kura Oncology, Inc.
Kura Oncology, Inc. (KURA) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $397.7K.
Where they traded
Last open-market purchase: August 24, 2026 , by WILSON TROY EDWARD .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| WILSON TROY EDWARD | President and CEO | Buy | 100,000 | $12.39 | $1.2M | 479,194 | |
| Powl Brian T. | Chief Commercial Officer | Sell 10b5-1 | 4,345 | $11.89 | $51.7K | 169,269 −2.5% of holding | |
| Bair Teresa Brophy | Chief Legal Officer | Sell 10b5-1 | 31,487 | $12.63 | $397.7K | 195,444 −13.9% of holding | |
| WILSON TROY EDWARD | President and CEO | Buy | 100,000 | $11.12 | $1.1M | 379,194 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.